Beleaguered Mallinckrodt plc MNK announced positive top-line results from a late-stage study on experimental StrataGraft regenerative tissue for the treatment of deep partial-thickness thermal burns.
Today, the U.S. Food and Drug Administration approved StrataGraft for the treatment of adult patients with thermal burns containing intact dermal elements (remaining deep skin layers) for which ...
The US Food and Drug Administration (FDA) has approved a novel regenerative therapy that could be an alternative to autografting for treating adults with severe burns. The new treatment, StrataGraft, ...
STAINES-UPON-THAMES, United Kingdom, April 12, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that Stratatech, a Mallinckrodt ...
STAINES-UPON-THAMES, United Kingdom, June 15, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced it will present data from the pivotal Phase 3 ...
DUBLIN, Feb. 12, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it is ...
Mallinckrodt plc MNK announced that its subsidiary, Stratatech, has completed the rolling submission of a biologics license application (BLA) for its investigational product, StrataGraft a ...
Mallinckrodt plc, a leading global biopharmaceutical company, today announced publication of results of its Phase 1b clinical trial of StrataGraft ®, an investigational regenerative tissue, in Burns, ...
The approval was based on data from the 2 randomized clinical studies that assessed StrataGraft in a total of 101 adults with deep partial thickness thermal burns. The Food and Drug Administration ...
Please provide your email address to receive an email when new articles are posted on . A phase 3 trial showed the majority of burns treated with StrataGraft did not require autografting and achieved ...
MADISON, Wis.--(BUSINESS WIRE)--Stratatech Corp., a leading regenerative medicine company, announced today that it has been awarded a contract valued at up to $247 million by the Biomedical Advanced ...
The US Food and Drug Administration (FDA) has approved a novel regenerative therapy that could be an alternative to autografting for treating adults with severe burns. The new treatment, StrataGraft, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results